Protein kinase C (PKC) signaling regulates osteoblast differentiation, but little is known about its downstream effectors. We examined the effect of modulating PKC activity on osteogenic transcription factors and found that the protein level of Msx2 is affected. Msx2 is induced by osteogenic signals such as BMPs and it plays critical roles in bone formation and osteoblast differentiation. Here, we examined the role of PKC signaling in regulating the function of Msx2. We found that the inhibition of PKC signaling enhances osteogenic differentiation in BMP2-stimulated C2C12 cells. Treatment with inhibitors of PKC activity or overexpression of kinase-defective (KD), dominant-negative mutant PKC isoforms strongly reduced the level of Msx2 protein. Several PKC isoforms (α, β, δ, and ζ) interacted with Msx2, and PKCβ phosphorylated Msx2 at Thr135 and Thr141. Msx2 repressed the transcriptional activity of the osteogenic transcription factor Runx2, and this repression was relieved by inhibition of PKC activity or overexpression of the KD mutant PKC isoforms. In addition, PKC prolonged the half-life of Msx2 protein. These results suggest that PKC signaling modulates osteoblast differentiation, at least in part, through the regulation of Msx2.
Introduction
Protein kinase C (PKC) signaling mediates various cellular functions such as cell proliferation and differentiation. Studies have shown that PKC signaling also regulates osteoblast differentiation. PKC proteins are serine/threonine kinases, and the PKC family consists of 11 isoforms that can be divided into three subgroups: Ca 2+ -dependent conventional PKCs (α, β1, β2, γ), diacylglycerol (DAG)-dependent novel PKCs (δ, ε, η, θ), and Ca
2+
/DAG-independent atypical PKCs (λ/ι and ζ). Several PKC isoforms are expressed during the osteogenic differentiation of MC3T3-E1 pre-osteoblastic cells and they play distinct roles [1] . PKCs mediate the signaling of various osteogenic regulators such as parathyroid hormone (PTH), FGFs, BMPs, oxysterol and estrogen [2] [3] [4] . In rat and human osteoblast-like cell lines, PKC signaling is necessary for PTH-induced cell proliferation and activation of ERKs, and it can induce the transcription of Osteocalcin [5] [6] [7] . PKC β2, δ and θ have been reported to enhance BMP4-induced osteogenic differentiation [8] . However, the function of PKCα is controversial in that PKCα is necessary for bFGF-induced bone formation yet it suppresses the osteogenic differentiation of rat primary osteoblasts [9, 10] . Although studies have established that PKC signaling regulates bone formation, the downstream effectors of PKC signaling during this process are largely unknown. PKC signaling regulates the expression of the osteogenic transcription factor Runx2, and it regulates the activity of Runx2 via phosphorylation upon FGF stimulation or mechanical stress [11, 12] .
We examined the effect of modulating PKC activity on the levels of several osteogenic transcription factors and found that PKC activity modulates the level of Msx2 protein. Msx2 (msh homeobox homolog 2) belongs to a family of transcription factors that consist of three vertebrate homologs of Drosophila muscle segment homeobox (msh). Msx2 plays critical roles in bone development. Individuals with a gainof-function mutation in the MSX2 gene suffer Boston-type craniosynostosis, characterized by premature fusion of skull bones and abnormalities in certain craniofacial bones [13] . In addition, haploinsufficiency of the MSX2 gene in human causes defects in skull ossification [14] . Msx2-null mice also exhibit defects in endochondral bone formation due to defects in the proliferation of osteoprogenitors [15] . However, the precise function of Msx2 is still controversial. Msx2 promotes the osteogenic differentiation of skeletal progenitors by reducing Dkk1 expression and subsequently enhancing Wnt signaling [16] . In primary aortic myofibroblasts, Msx2 inhibits adipogenic differentiation through the interaction with C/EBPα and subsequent reduction of PPARγ expression, and it promotes BMP-induced osteogenic differentiation [17] . These reports suggest that Msx2 has positive roles in osteogenic differentiation. However, other studies have shown that Msx2 can inhibit osteogenic differentiation. Msx2 represses the expression of bone markers such as Alkaline phosphatase and Osteocalcin [18] [19] [20] [21] , and it inhibits the function of osteogenic transcription factors such as Runx2, Dlx3 and Dlx5 [22, 23] . In addition, Msx2 inhibits calvarial osteoblast differentiation in vivo and the mineralization of osteoblasts in vitro, whereas it stimulates osteoprogenitor proliferation at the osteogenic front of the suture [24] . Although studies have established that Msx2 plays critical roles during bone development, the precise control mechanisms by upstream regulators of Msx2 are largely unknown.
Both PKC signaling and Msx2 play essential roles in bone formation, yet the potential interaction and regulation between them have not been investigated. In this study, we examined the regulation of Msx2 function by PKC signaling. We found evidence that PKC activation represses BMP2-induced osteoblast differentiation while it increases the protein stability of Msx2. PKC inhibition relieved the suppression of Runx2 transcriptional activity by Msx2. We also found that various PKC isoforms interact with Msx2, and PKCβ can phosphorylate Msx2 at Thr135 and Thr141. Furthermore, mutations at Thr135 of Msx2 affected Msx2 protein stability. Finally, mutations in the putative PKC phosphorylation target sites on Mxs2 abolished the ability of PKC signaling to modulate the repressive ability of Msx2 on Runx2 transcriptional activity. These results suggest that PKC signaling enhances the activity of Msx2 post-translationally and inhibits osteogenic differentiation, at least in part, through Msx2.
Materials and methods

Cell culture
C2C12 mouse myoblast and 293 human embryonic kidney cell lines were maintained at 37°C, 5% CO 2 in DMEM supplemented with fetal bovine serum (20% or 10% respectively), antibiotics, and antimycotics. All culture media and supplements were purchased from Invitrogen.
Plasmids, antibodies and reagents
C-terminal HA-tagged human PKC α, β1, δ, ζ expression plasmids were obtained from Dr. J.-W. Soh (http://www.pkclab.org). N-terminal epitope-tagged human Msx2 expression plasmids were constructed in a CMV promoter-derived mammalian expression vector (pCS4+). T135A, T135E, and T141A Msx2 mutants were generated by PCR-based mutagenesis and confirmed by DNA sequencing. ALP-Luc, Cyclin D1-Luc, and OC-Luc reporter plasmids were generously provided by Dr. N. Kim (Chonnam National University). Antibodies against GFP (B-2), Msx2 (M-70) and Myc (9E10) (Santa Cruz Biotechnology), HA (12CA5, Roche Applied Science) and α-tubulin (DM1A, Cell Signaling Technology) were used. Gö6976, Gö6983, MG132 and PMA were purchased from EMD4Biosciences. Recombinant human BMP-2 (355-BM) was purchased from R&D Systems.
RNA preparation and semi-quantitative RT-PCR
Total cellular RNA was prepared using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. cDNAs were synthesized using SuperScript III First-Strand Synthesis System (Invitrogen). The following conditions were used for the PCR amplification of cDNA: initial denaturation at 94°C for 1 min; 28-30 cycles of denaturation at 94°C for 30 s, annealing at a temperature optimized for each primer pair for 30 s, and extension at 72°C for 30 s; final extension at 72°C for 5 min. The following PCR primers were used: ALP, forward 5′-GAT CAT TCC CAC GTT TTC AC-3′ and reverse 5′-TGC GGG CTT GTG GGA CCT GC-3′; ColIA, forward 5′-TCT CCA CTC TTC TAG GTT CCT-3′ and reverse 5′-TTG GGT CAT TTC CAC ATG C-3′; GAPDH, forward 5′-ACC ACA GTC CAT GCC ATC AC-3′ and reverse 5′-TCC ACC ACC CTG TTG CTG TA-3′. GAPDH was used as an internal control.
Alkaline phosphatase (ALP) staining
Cells were fixed in 4% paraformaldehyde for 10 min, washed several times with PBS and stained with NBT/BCIP solution (SigmaAldrich) for 15 min. All steps were performed at room temperature.
DNA transfection and reporter assays
Transient transfections were performed using the calcium phosphate method or effectene plus (Qiagen). For immunoblotting, GFP was co-transfected as an internal control for transfection efficiency. For luciferase assays, 293 cells were seeded on 24-well plates the day before transfection. pCMV-β-Gal plasmid was co-transfected as an internal control for transfection efficiency. Thirty-six hours after transfection, luciferase activities were measured using Luciferase Reporter Assay Kit (Promega) and normalized with corresponding β-galactosidase activities. Each experiment was repeated three times, and the averages and standard deviations of a representative experiment are shown.
Immunoprecipitation and immunoblotting
Cells were lysed in an ice-cold lysis buffer [25 mM Hepes (pH 7.5), 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 10% glycerol, 25 mM NaF, 1 mM EDTA, 1 mM Na 3 VO 4 , 250 μM PMSF, 10 μg/ml leupeptin, and 10 μg/ml aprotinin]. Lysates were cleared by centrifugation. For immunoblotting of supernatants, α-tubulin was used as a loading control. For immunoprecipitation, the supernatants were incubated with appropriate antibodies and protein A or G-Sepharose beads. Lysate supernatants or immunoprecipitated proteins were resolved by SDS-PAGE and transferred to PVDF membranes. Proteins were visualized using appropriate primary antibodies, horseradish peroxidase-coupled secondary antibodies and chemiluminescence Western blotting reagent (GE Healthcare). were terminated by adding SDS-sample buffer and analyzed by SDS-PAGE and autoradiography.
In vitro kinase assay
Statistical analysis
All experiments were performed with triplicate independent samples and were repeated at least twice, giving qualitatively identical results. Results are expressed as mean ± standard error of the mean. Data were analyzed using Student's t-test, with p b 0.05 indicating significance.
Results
PKC activity suppresses osteoblast differentiation in vitro
To examine the effects of PKC activity on osteoblast differentiation, we first analyzed whether PKC activator or inhibitor modulates the expression of osteoblast markers in BMP2-stimulated C2C12 cells. The C2C12 mouse myoblast cell line maintains osteogenic potential and its differentiation pathway can be shifted from myoblastic to osteoblastic upon BMP2 stimulation [25] . BMP2 induced the expression of two osteoblast markers, Alkaline phosphatase (ALP) and Collagen type I A (ColIA) (Fig. 1A) . PKC activation, with a PKC activator PMA, significantly reduced the BMP2-induced expression of ALP and ColIA. Conversely, PKC inhibition with Gö6983 further increased the BMP2-induced marker expression. However, another PKC inhibitor Gö6976 slightly increased the expression of ALP but did not alter the expression of ColIA significantly. Gö6976 and Gö6983 have different specificities for PKC; Gö6976 inhibits Ca 2+ -dependent PKC isoforms (α, β, γ) and PKD, whereas Gö6983 inhibits all PKC isoforms but does not inhibit PKD [26, 27] .
Next, we examined whether PKC activity affects the BMP2-induced expression of ALP protein when assayed by ALP staining. BMP2 increased the ALP staining in a dose-dependent manner (Fig. 1B , top panel). Treatment with Gö6976 or Gö6983 enhanced the BMP2-induced increase of ALP staining in a dose-dependent manner (Fig. 1B , second and third panels). Conversely, treatment with increasing concentrations of PMA gradually decreased the BMP2-increased ALP staining (Fig. 1B, bottom panel) . However, this decrease by PMA is not likely due to a decrease in cell proliferation as PMA treatment did not decrease the proliferation of C2C12 cells (data not shown, also see Fig. 6C ). We also examined the effect of PKC inhibition on the expression of a luciferase reporter (ALP-Luc) containing the promoter region of ALP. BMP2 induced the expression of ALP-Luc in C2C12 cells, and PKC inhibitors further increased the reporter expression (Fig. 1C) . These results suggest that PKC activity suppresses the BMP2-induced osteogenic differentiation of C2C12 cells.
PKCs affect the expression of Msx2 protein
PKCs may affect osteoblast differentiation by modulating the function of target proteins. Therefore, we examined the effect of modulating PKC activity on the levels of several osteogenic transcription factors and found that PKC activity modulates the level of Msx2 protein. Inhibition of PKC, either by Gö6976 or Gö6983, decreased the level of overexpressed Msx2 protein in 293 cells ( Fig. 2A) . Conversely, PKC activation increased the level of overexpressed Msx2 protein (Fig. 2B) . We also examined the effect of modulating PKC activity on the level of endogenous Msx2 protein in C2C12 cells. C2C12 cells expressed low levels of Msx2, if any at all, under non-differentiating conditions. BMP2 stimulation increased the level of Msx2, but this increase was abolished upon PKC inhibition (Fig. 2C) . Conversely, PKC activation significantly increased the level of Msx2 above that by BMP2 alone. These results suggest that PKCs modulate the level of Msx2 protein. Previous studies have reported that Msx2 acts as a negative transcriptional regulator for osteogenesis at multiple steps [28] . Our results suggest that PKC activity suppresses osteogenic differentiation while increasing the level of Msx2 protein, indicating that PKCs may suppress osteogenic differentiation by increasing the level and therefore the osteogenesis-suppressing activity of Msx2.
Next, we examined which PKC isoform is able to affect the level of Msx2 protein. PKCβ increased the level of overexpressed Msx2, but PKC α, δ and ζ did not have any significant effects (Fig. 2D) . A kinase-defective (KD) mutant form of PKCβ decreased Msx2 protein level, and PKC α and δ KD mutants also did so but to lesser degrees than the PKCβ mutant. PKCζ KD mutant did not have any significant effect. These results suggest that PKCs, particularly the Ca
2+
-dependent PKC isoforms, affect the level of Msx2 protein.
Msx2 interacts with PKCs and is phosphorylated by PKCβ in vitro
PKCs modulate the function of target proteins through direct modifications or through modulation of the targets' upstream effectors. Therefore, we examined the possibility of interaction between PKC isoforms and Msx2 by co-immunoprecipitation of these proteins expressed in 293 cells. All wild-type PKC isoforms, we tested, coimmunoprecipitated with Msx2 (Fig. 3A) . However, the KD mutants of PKC α and β interacted with Msx2 to significantly lesser degrees than their wild-type counterparts.
Given that PKCs interacted with Msx2, we next used in vitro kinase assays to examine whether PKC phosphorylates Msx2. Recombinant active PKCβ was used for this assay, as the protein level of Msx2 was affected more by PKCβ than by other PKC isoforms (Fig. 2D) . PKCβ phosphorylated Msx2 (Fig. 3B) . Msx2 has two potential PKC phosphorylation target sites (Thr135 and Thr141). To determine if PKC phosphorylates Msx2 at these sites, we generated threonineto-alanine substitution mutants (T135A and T141A) of Msx2 and examined the phosphorylation of these mutants by PKCβ. Phosphorylation by PKCβ was greatly reduced for Msx2 mutants when compared to that of the wild-type Msx2 (Fig. 3B) . These results suggest that Thr135 and Thr141 on Msx2 are major, if not the exclusive, phosphorylation target sites of PKCβ.
PKC activity prevents Msx2 ubiquitination
PKC activation enhanced and PKC inhibition abolished the BMP2-induced increase in Msx2 protein levels in C2C12 cells (Fig. 2C) . PKC may modulate Msx2 protein level through the regulation of Msx2 transcription, translation or protein stability. PKC inhibition or activation did not significantly affect the level of Msx2 transcript (Fig. 4A) , indicating that PKC activity likely modulates Msx2 expression at the protein level rather than the transcription level. A major pathway for the modulation of cellular protein levels is the ubiquitin and proteosome-mediated degradation system, in which proteins are committed to proteosomal degradation by the ligation of ubiquitin (Ub) [29, 30] . We therefore examined the ubiquitination of Msx2. The level of overexpressed Msx2 was decreased with co-transfection of Ub but was increased in the presence of a proteosome inhibitor MG132 (Fig. 4B, left panel) . Also, the level of ubiquitinated Msx2 was increased upon Ub co-transfection, even when the level of total Msx2 protein was decreased (Fig. 4B, right panel) . These results suggest that the Msx2 protein level can be regulated by the ubiquitinproteosome degradation pathway. We next examined whether PKC activity regulates the protein stability of Msx2 by analyzing the effect of PKC on the half-life of Msx2 protein. PKC activation prolonged the half-life of Msx2 in 293 cells (Fig. 4C) . Similarly, the half-life of Msx2 protein was increased in the presence of wild-type PKCβ but significantly reduced in the presence of the PKCβ KD mutant. We also examined the effect of a phospho-mimetic mutation of Msx2 at Thr135 (T135E, a threonine to glutamic acid substitution) on the half-life of Msx2 protein. The halflife of Msx2(T135E) was significantly longer than that of wild-type Msx2 in 293 cells (Fig. 4D) .
Finally, we examined the effect of the T135E mutation on the halflife of Msx2 protein in C2C12 cells. The protein level of wild-type Msx2 was reduced upon PKC inhibition whereas that of Msx2(T135E) mutant was not affected (Fig. 4E) . These results suggest that the phosphorylation of Msx2 by PKC may increase the protein stability of Msx2. 
PKC inhibition relieves the suppression of Runx2 transcriptional activity by Msx2
Previous studies have reported that Msx2 can inhibit osteoblast differentiation through the repression of Runx2 transcriptional activity [31] . Therefore we analyzed the effect of PKC activity on this ability of Msx2. An Osteocalcin promoter luciferase reporter (OC-Luc) contains Runx2-responsive elements. Runx2 induced the expression of OC-Luc (Fig. 5A) . Msx2 decreased the Runx2-induced expression of OC-Luc, and PKC inhibitors relieved this suppression in dose-dependent manners. We then examined the effects of overexpressing PKC isoforms on the ability of Msx2 to suppress the Runx2 transcriptional activity. Runx2-mediated OC-Luc activation was significantly restored by the KD mutant of PKC β or δ and to a lesser degree by PKC α or ζ KD mutant (Fig. 5B) . These results suggest that the suppressive effect of Msx2 on Runx2 transcriptional activity can be modulated by PKC.
Msx2 is associated with osteoprogenitor cell proliferation
Satokata et al. reported that Msx2-null mice exhibit defects in the proliferation of osteoprogenitors at the osteogenic front during calvarial morphogenesis [15] . In addition, a recent study suggests that Msx2 increases the proliferation of osteoprogenitors [32] . BMP2 stimulation increased the expression of the cell cycle control protein Cyclin D1 in C2C12 cells, and this increase was further enhanced upon Msx2 overexpression in a dose-dependent manner ( Fig. 6A and B) . BMP2 also stimulated the expression of CDK4, the kinase partner of Cyclin D1, but CDK4 expression was not significantly changed with Msx2. To examine the possible regulation of PKC activity in Msx2-induced cell cycle change, the expression of a luciferase reporter containing Cyclin D1 promoter (Cyclin D1-Luc) was analyzed in 293 cells. Msx2 increased the expression of Cyclin D1-Luc, and this was further enhanced by PKC activation (Fig. 6C) . PKC inhibition reduced Msx2-induced reporter expression only slightly (Fig. 6C) . These results suggest that Msx2 increases the osteoprogenitor proliferation, and PKC activity may enhance this function of Msx2. These results also suggest that the decrease of BMP2-induced ALP staining upon PKC activation (Fig. 1B) is not due to a decrease in the cell proliferation.
Discussion
In this study, we provide evidence that PKC activity stabilizes BMP2-induced Msx2 protein expression through the phosphorylation of Msx2, and that PKC activity may suppress BMP2-induced osteogenic differentiation, at least in part, through the stabilization of Msx2 and the inhibition of Runx2 transcriptional activity by Msx2. We also found that PKC activity promotes the osteoprogenitor proliferation.
Thr135 and Thr141 in Msx2 can be phosphorylated by PKCβ, and Thr135 is important for regulating the protein stability of Msx2 by PKCs. Studies suggest that ERK and p38 MAPK pathways are particularly important for the up-regulation of Msx2 in advanced pancreatic cancer cells [33] . This raises the possibility that protein kinases may affect the function of Msx2. However, the precise regulation of Msx2 function by different kinases during osteogenesis remains unclear. We investigated the ability of various kinases to modulate Msx2 function, and found that Msx2 is affected more by PKC than by other kinases (data not shown). Identifying the precise phosphorylation target sites for PKC isoforms on Msx2 and the effect of Msx2 phosphorylation by PKC isoforms on the function of Msx2 in vivo will further enhance the understanding of the regulatory roles of PKC isoforms and the function of Msx2 during osteoblast differentiation and bone formation.
A recent study suggested that PKCα suppresses osteogenic differentiation of MC3T3-E1 cells [10] . This conclusion was based on the facts that treatment with Gö6976 or Gö6983, but not with a PKCβ inhibitor, and the knockdown of PKCα enhance osteoblastic differentiation. We also found that both Gö6976 and Gö6983 enhance the osteogenic differentiation of C2C12 cells. Gö6976 inhibits only the Ca 2+ -dependent PKC isoforms (α, β, γ) and PKD, while Gö6983 inhibits all isoforms of PKC. Our results indicate that, in 293 cells, both Gö6976 and Gö6983 decrease the level of overexpressed Msx2 protein, and PKC α, β, δ, and ζ all interacted with Msx2. However, only PKCβ had significant effect to the Msx2 protein level. It is possible that PKC α and β suppress osteoblast differentiation by affecting the function of distinct target proteins and/or that different osteogenic cell lines express distinct PKC isoforms. Therefore identifying the targets of each PKC isoform will help us understand the precise roles of PKC isoforms. In addition, the expression/activation patterns of PKC isoforms and the effects of knockdown of PKC isoforms during osteoblast differentiation need to be compared. Studies have indicated that Msx2 represses the transcriptional activities of osteogenic transcription factors such as Runx2, Dlx3 and Dlx5 [31, 34] . We also found that Msx2 can repress the transcriptional activity of Runx2, and furthermore we found that PKC activity can modulate this activity of Msx2. Meanwhile, studies suggest that Msx2 promotes the proliferation of osteoprogenitors. We found that Msx2 increases the expression of Cyclin D1 protein, a critical regulator of the cell cycle transition from G1 to S phase. Hu et al. suggested that Msx1 plays a positive role in osteoblast proliferation via the induction of Cyclin D1 expression [35] . PKC β1 and β2 regulate the expression of Cyclin D1 in other mammalian cells [36] . The increased expression of Cyclin D1 signifies cell-cycle progression and cell proliferation, whereas the decreased expression of Cyclin D1 is a hallmark of differentiation. Taken together, the results of our and others suggest that Msx2 suppresses the differentiation but promotes the proliferation of osteogenic cells. However, Msx2 mutant mice exhibit defects in bone formation and a reduction of osteoblasts [15] . It is likely that the phenotypes of Msx2-null mice are due to the reduction of osteoprogenitor proliferation but not due to the reduction of osteoblast differentiation per se.
In conclusion, we suggest that the phosphorylation and subsequent stabilization of Msx2 by PKCβ can prevent osteogenic differentiation, and this suppression of osteogenic differentiation may be due to the repression of Runx2 transcriptional activity and the simultaneous promotion of osteoprogenitor proliferation. 
